Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVE-1: iclaprim versus vancomycin for acute bacterial skin and skin structure infections
2015-002669-45Phase 3Completed
- Sponsor
- Motif Bio plc
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Iclaprim in acute bacterial skin and skin structure infection (ABSSSI) and Not applicable (2 arms), sponsored by Motif Bio plc. Primary endpoint: Early clinical response at 48 to 72 hours. Started Jan 2016; status: completed.
02
Drugs
Iclaprim
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)Not applicable
Beyond the preview
Go deeper on 2015-002669-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002669-45.